Switzerland and the United States signed a joint declaration of intent on 14 November 2025 that brought the US tariff on Swiss goods down from 39% to a ceiling of 15%. One year later no legally binding agreement has been signed. The page on which Switzerland's State Secretariat for Economic Affairs (SECO) tracks the file, read on 16 November 2026, announces no signing and no date for one, and still describes the talks as open.1 6
Die Verhandlungen mit den USA über ein Handelsabkommen laufen weiter.
The negotiations with the USA on a trade agreement are continuing.1
What Swiss exporters pay now
The legal basis of the tariff has changed twice since the declaration. The US Supreme Court struck down the emergency tariffs on 20 February 2026. Washington replaced them with a temporary 10% surcharge, which lapsed on 24 July 2026, and then with tariffs under Section 301 of the US Trade Act, the law that lets the US trade representative act against foreign practices he judges unfair. In this case the stated ground is that the countries concerned do too little to stop imports made with forced labour.1 7
For Switzerland the Section 301 tariff is a top-up, not an addition. SECO describes a variable surcharge of up to 12.5% that counts the ordinary duty towards the total: a product with an ordinary duty of 5% pays a further 7.5%, and a product whose ordinary duty is already 12.5% or more pays nothing extra. The US trade representative's notice of 23 July 2026 puts Switzerland in a group of five, with the European Union, Taiwan, Japan and South Korea, that is charged net of the ordinary duty. Seventeen economies pay a flat 10% and the rest a flat 12.5% on top of it.1 7
That leaves Swiss goods below the 15% ceiling of the declaration. Sector tariffs under Section 232, the US law on imports held to threaten national security, are separate. They cover steel, aluminium, copper and cars, and SECO says they are not added to the Section 301 tariff.1
The medicines tier
Medicines matter most to Switzerland. According to an analysis published by Migros Bank on 9 November 2026, which cites the Swiss customs office, pharmaceutical exports exceeded 118 billion francs in 2025, about four in every ten francs the country earned from goods exports, and just over a quarter of them went to the United States.4
The US proclamation on pharmaceuticals, published in April 2026, sets 100% as the default rate on patented medicines and their ingredients. It sets 15% for products of Switzerland and Liechtenstein, the same rate as for Japan, the EU and South Korea, and 10% for the United Kingdom. Firms with approved plans to move production to the United States pay 20%. Generic medicines are left out for now. The tariff applied from 31 July 2026 to the companies the proclamation names and from 29 September 2026 to all others.3
The two largest Swiss producers are largely outside it. Under the proclamation, companies that have signed pricing agreements with the US government pay nothing until 20 January 2029. Novartis and Roche's US subsidiary Genentech were among nine firms that reached such agreements in December 2025, in return for lower prices and investment, the Swiss news agency Keystone-SDA reported at the time. Roche pledged 50 billion dollars and Novartis confirmed 23 billion dollars.3 4 6
Migros Bank's economists read this as limited tariff risk for the two groups until the end of 2028, while still naming US trade policy as the main danger to the sector:4
Aktuell stellt die US-Zollpolitik das grösste Risiko für die Branche dar.
At present, US tariff policy is the greatest risk for the industry.4
What each side has done, and what it has not
Bern's side of the bargain included zero duties on US industrial goods, tariff quotas for US farm products and at least 200 billion dollars of investment by Swiss companies in the United States over five years. On 29 June 2026 the Federal Council, Switzerland's government, restated that it stands by the declaration and said it would carry out further points by changing its own regulations, including easier recognition of US standards for medical devices and cars. It attached a condition addressed to Washington:1 2
Gleichzeitig wird die Einhaltung der Absichtserklärung seitens USA erwartet.
At the same time, the USA is expected to keep to the declaration of intent.2
The original aim was a signed agreement by the end of March 2026. That date passed, and the Swiss broadcaster SRF reported in April, after Economics Minister Guy Parmelin met the US trade representative, Jamieson Greer, in Washington, that there was no breakthrough and no new deadline. Washington has published no statement on the Swiss talks among the sources read for this article.5
The trade figures
Swiss monthly trade has swung sharply since the medicines tariff began. Customs figures reported by the agency AWP show exports to the United States fell by almost 30% in August 2026 and recovered by 8.5% in September to 3.32 billion francs. Chemical and pharmaceutical exports as a whole dropped by just over 32% in August and rose 0.5% in September.8
The October trade figures have not yet been published. The open question is whether a binding text arrives before the cover that the two largest drug makers hold runs out in January 2029, and whether the 15% ceiling, which rests on a declaration and not on a treaty, holds until then.3 8